Masimo to Be Acquired by Danaher in Merger

Masimo ( (MASI) ) has issued an update.

On February 16, 2026, Masimo Corporation agreed to be acquired by Danaher Corporation in an all-cash merger that values Masimo at $180 per share, or about $9.9 billion, with the deal unanimously approved by both companies’ boards and announced publicly on February 17, 2026. Masimo will become a standalone business unit within Danaher’s Diagnostics segment, with detailed terms covering treatment of equity awards, a support agreement securing votes from major shareholder Politan Capital Management, customary regulatory and shareholder conditions, and provisions for potential competing bids, positioning Danaher to strengthen its acute-care diagnostics offering while delivering a cash exit at a premium valuation to Masimo shareholders.

If completed in the second half of 2026 as expected, the merger will take Masimo private under Danaher’s ownership, delist its shares from Nasdaq, and more tightly align its monitoring technologies with a larger diagnostics portfolio. The transaction includes a substantial termination fee, extensive no-shop and matching rights, and a framework for Masimo’s continued autonomous operation within Danaher, signaling a strategic consolidation in the patient-monitoring space with implications for customers, employees, and investors amid regulatory and execution risks typical of large healthcare deals.

The most recent analyst rating on (MASI) stock is a Hold with a $180.00 price target. To see the full list of analyst forecasts on Masimo stock, see the MASI Stock Forecast page.

Spark’s Take on MASI Stock

According to Spark, TipRanks’ AI Analyst, MASI is a Neutral.

The score is held back primarily by weak trailing profitability and revenue pressure reflected in the financial statements, with mixed technical trend signals and limited valuation support due to losses. Offsetting these, management’s recent guidance and execution signals (margin expansion, raised EPS outlook) plus positive corporate updates provide meaningful upside support, but not enough to overcome the weaker trailing fundamentals.

To see Spark’s full report on MASI stock, click here.

More about Masimo

Masimo Corporation is a global medical technology company that develops noninvasive patient-monitoring technologies, including advanced measurements, sensors, patient monitors, and automation and connectivity solutions. Its Masimo SET pulse oximetry platform is widely used in acute care, with an estimated 200 million patients monitored annually and adoption at all top 10 U.S. hospitals in Newsweek’s 2025 ranking.

The company focuses on improving clinical outcomes and reducing the cost of care across hospitals and new care settings, positioning itself as a leader in high-performance pulse oximetry and monitoring systems. Its technologies support clinicians in acute and critical care environments worldwide and underpin Masimo’s role as a key innovator in patient monitoring solutions.

Average Trading Volume: 751,598

Technical Sentiment Signal: Sell

Current Market Cap: $6.99B

See more data about MASI stock on TipRanks’ Stock Analysis page.